Mucosal Vaccine Platforms for Respiratory and Enteric Pathogens: Current Advances, Key Barriers, and Translational Opportunities
Immunology Research and Perspectives · 16.06.2026 · 2 (2) · 1-25
DOI: 10.64229/hbskck72 ↗Kurz gefasst
Fachartikel in der Zeitschrift Immunology Research and Perspectives, online erschienen am 16.06.2026. Verfasst von Shoaib Manzoor. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Respiratory and enteric pathogens cause significant global morbidity and mortality, transmitting efficiently across mucosal surfaces. Conventional injectable vaccines primarily induce systemic immunity, offering limited protection at these entry sites. Mucosal vaccination is a promising strategy to elicit local and systemic immunity, particularly secretory immunoglobulin A (IgA) and tissue-resident memory T cells, which block infection and reduce transmission. Licensed mucosal vaccines, including intranasal influenza (FluMist), oral rotavirus (Rotarix/RotaTeq), oral polio, and oral cholera (Dukoral) vaccines, demonstrate the feasibility of this approach. This review summarizes the immunological basis of mucosal immunity and evaluates delivery routes like intranasal and oral administration. A systematic search of PubMed, Scopus, and Web of Science (Jan 2020-Mar 2026) was conducted. Major vaccine platforms__live attenuated vectors, protein subunits, and nucleic acid-based systems__are discussed alongside adjuvants, nanoparticles, and bioadhesive formulations. Applications to key respiratory (influenza, SARS-CoV-2, RSV, Mycobacterium tuberculosis) and enteric (Shigella, ETEC, Campylobacter, rotavirus) pathogens are highlighted. Critical barriers include mucosal tolerance, antigen degradation, and manufacturing complexity. Emerging innovations in mRNA technology, synthetic biology, and artificial intelligence offer new opportunities to overcome these obstacles, enhancing herd immunity and global control of infections.
Zitieren
APA
Manzoor, S. (2026). Mucosal Vaccine Platforms for Respiratory and Enteric Pathogens: Current Advances, Key Barriers, and Translational Opportunities. Immunology Research and Perspectives, 2(2), 1-25. https://doi.org/10.64229/hbskck72
Vancouver
Manzoor S. Mucosal Vaccine Platforms for Respiratory and Enteric Pathogens: Current Advances, Key Barriers, and Translational Opportunities. Immunology Research and Perspectives. 2026;2(2):1-25. doi:10.64229/hbskck72
BibTeX
@article{Manzoor2026,
author = {Manzoor, Shoaib},
title = {Mucosal Vaccine Platforms for Respiratory and Enteric Pathogens: Current Advances, Key Barriers, and Translational Opportunities},
journal = {Immunology Research and Perspectives},
year = {2026},
volume = {2},
number = {2},
pages = {1--25},
doi = {10.64229/hbskck72}
}
EUVIMED